Burleson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Burleson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6	Closed	-$2K	–	493
2022 Q2	$2K	Buy	+6	New	+$1.61K	﹤0.01%	352

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Burleson & Co's VRTX Position: Q3 2022 in Review

Burleson & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 6 shares — an estimated $2K sold.

Burleson & Co first reported a position in VRTX in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 1,125 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Burleson & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Burleson & Co sold 6 Vertex Pharmaceuticals shares in Q3 2022, an estimated $2K.
Burleson & Co first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Burleson & Co's Vertex Pharmaceuticals position peaked at $2K in Q2 2022.
1,125 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Burleson & Co's 13F filing for Q3 2022, filed 17 Oct 2022.